Literature DB >> 12399420

The alphaVbeta3 integrin regulates insulin-like growth factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptor.

Laura A Maile1, David R Clemmons.   

Abstract

The alphaVbeta3 integrin is an important determinant of IGF-I-stimulated receptor phosphorylation and biological actions. Blocking ligand occupancy of alphaVbeta3 with the distintegrin echistatin reduces IGF-I-stimulated receptor phosphorylation, and it inhibits cellular migration and DNA synthesis responses to IGF-I. We have shown that recruitment of the tyrosine phosphatase Src-homology 2-containing phosphotyrosine phosphatase-2 (SHP-2) to the IGF-I receptor (IGF-IR) is an important determinant of the duration of IGF-IR phosphorylation. These studies were undertaken to determine whether an alteration in the recruitment of SHP-2 to the receptor in the presence of echistatin could account for the decrease in receptor phosphorylation. Following an overnight exposure of smooth muscle cell cultures to echistatin, the addition of IGF-I was accompanied by rapid dephosphorylation of IGF-IR compared with cells exposed to media alone. This was associated with an increase in the rate of SHP-2 recruitment to the IGF-IR. In cells expressing a catalytically inactive form of SHP-2, prior exposure to echistatin had no effect on the rate of receptor dephosphorylation. In contrast to the usual physiologic situation in which following IGF-I exposure SHP-2 is recruited to IGF-IR via SHP-2 substrate-1 (SHPS-1) in the presence of echistatin, SHPS-1 was not used for SHP-2 recruitment. Our findings show that IRS-1 may substitute for SHPS-1 under these conditions. These results demonstrate that the activation state of alphaVbeta3 is an important regulator of the duration of IGF-IR phosphorylation and subsequent downstream signaling and that this regulation is mediated through changes in the subcellular localization of SHP-2.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399420     DOI: 10.1210/en.2002-220395

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  13 in total

1.  Endogenous IGF-I and alphaVbeta3 integrin ligands regulate increased smooth muscle hyperplasia in stricturing Crohn's disease.

Authors:  Robert S Flynn; Karnam S Murthy; John R Grider; John M Kellum; John F Kuemmerle
Journal:  Gastroenterology       Date:  2009-09-12       Impact factor: 22.682

Review 2.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

3.  The association between integrin-associated protein and SHPS-1 regulates insulin-like growth factor-I receptor signaling in vascular smooth muscle cells.

Authors:  Laura A Maile; Jane Badley-Clarke; David R Clemmons
Journal:  Mol Biol Cell       Date:  2003-05-29       Impact factor: 4.138

4.  Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.

Authors:  Kristopher C Carver; Timothy M Piazza; Linda A Schuler
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

Review 5.  The insulin-like growth factor (IGF) receptor type 1 (IGF1R) as an essential component of the signalling network regulating neurogenesis.

Authors:  Alexander Annenkov
Journal:  Mol Neurobiol       Date:  2009-08-29       Impact factor: 5.590

6.  IGF-I signaling is essential for FSH stimulation of AKT and steroidogenic genes in granulosa cells.

Authors:  Ping Zhou; Sarah C Baumgarten; Yanguang Wu; Jill Bennett; Nicola Winston; Jennifer Hirshfeld-Cytron; Carlos Stocco
Journal:  Mol Endocrinol       Date:  2013-01-22

7.  Interaction between serine phosphorylated IRS-1 and beta1-integrin affects the stability of neuronal processes.

Authors:  Jin Ying Wang; Elisa Gualco; Francesca Peruzzi; Bassel E Sawaya; Giovanni Passiatore; Cezary Marcinkiewicz; Izabella Staniszewska; Pasquale Ferrante; Shohreh Amini; Kamel Khalili; Krzysztof Reiss
Journal:  J Neurosci Res       Date:  2007-08-15       Impact factor: 4.164

8.  Modulation of integrin antagonist signaling by ligand binding of the heparin-binding domain of vitronectin to the alphaVbeta3 integrin.

Authors:  Laura A Maile; Ariel W Aday; Walker H Busby; Ravi Sanghani; Umadevi Veluvolu; David R Clemmons
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

Review 9.  IGF-IR in neuroprotection and brain tumors.

Authors:  Elisa Gualco; Jin Ying Wang; Luis Del Valle; Katarzyna Urbanska; Francesca Peruzzi; Kamel Khalili; Shohreh Amini; Krzysztof Reiss
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

Review 10.  Novel strategies for the treatment of chondrosarcomas: targeting integrins.

Authors:  Jui-Chieh Chen; Yi-Chin Fong; Chih-Hsin Tang
Journal:  Biomed Res Int       Date:  2013-12-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.